TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04464980

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MMR
Description: MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MMR
Description: MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MMR
Description: MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MMR
Description: MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MMD
Description: MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MMD
Description: MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MMD
Description: MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MMD
Description: MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component.
Study: NCT04825743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zalunfiban
Description: zalunfiban is a novel small molecule inhibitor of the platelet αIIbβ3 receptor specifically designed for first medical contact therapy of ST-elevation myocardial infarction (STEMI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zalunfiban
Description: zalunfiban is a novel small molecule inhibitor of the platelet αIIbβ3 receptor specifically designed for first medical contact therapy of ST-elevation myocardial infarction (STEMI).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo will be prepared to those subjects assigned to placebo. Less than 1 mL (depending on subject's weight) will be administered by subcutaneous injection.
Study: NCT05119582

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOOsonix System ONE-M
Description: Selected neurofibromas will be treated by high intensity focused ultrasound. Untreated fibromas will be used for controls.
Study: NCT06069323

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation
Description: Pediatric patients with ASD and ADHD will be randomized both in active and sham groups.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation
Description: Pediatric patients with ASD and ADHD will be randomized both in active and sham groups.
Study: NCT06177847

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIS
Description: In the group with BIS where the anesthesia protocol is opened, namely the use of anesthetic gas, the anesthetic drug will be adjusted to the BIS value range of 40-60 or BIS-guided
Study: NCT04972825

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mind the Gap
Description: This intervention will help parents with children newly diagnosed with autism or other neurodevelopmental disorders learn how to navigate the system of acquiring services for their child. These parents will be assisted by a coach, an employee at the child's agency, that will help them through this process.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind the Gap
Description: This intervention will help parents with children newly diagnosed with autism or other neurodevelopmental disorders learn how to navigate the system of acquiring services for their child. These parents will be assisted by a coach, an employee at the child's agency, that will help them through this process.
Study: NCT06553508

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trochanteric bursa repaired
Description: As a routine procedure in our centre, the trochanteric bursa is left unrepaired after a hip arthroplasty.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trochanteric bursa unrepaired
Description: For the experimental arm, the trochanteric bursa is repaired after a hip arthroplasty. The conventional joint closure is performed after reduction and then the bursa is retrieved and repaired.
Study: NCT06395558

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Multimodal web-based intervention programme on anxiety, depression and cognitive impairment consisting of knowledge development sessions and practical/gaming sessions focused on different domains: cognitive competence, socio-relational competence and emotions/affectivity, and physical activity-nutrition
Study: NCT05384860

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auricular Trauma Protocol (ATP) Acupuncture
Description: Small filiform (needle) like needles use low frequency electrostimulation at eight ear points for 60 minutes while patient is sedated during surgery. All other aspects of the surgical procedure will go as planned according to the hospital's standard of care.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Acupuncture Group
Description: This involves not receiving the acupuncture treatment and surgery going entirely as normal according to the hospital's standard of care.
Study: NCT04704544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-rheumatology
Description: Participants will receive virtual visits via video conferencing and/or phone.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-rheumatology
Description: Participants will receive virtual visits via video conferencing and/or phone.
Study: NCT05520268

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional music therapy (CMT)
Description: CMT comprises both receptive and expressive musical activities (listening and reminiscing to music, singing, and moving to music) held in small groups (8 PWDs/group) for a duration of 10 weeks (2x60 min sessions/week) and led by a professional music therapist. For PWDs living in a care home, the CMT sessions are implemented as inpatient rehabilitation held at the care home. For PWDs living at home, the CMT sessions are implemented as outpatient rehabilitation held at a local day activity centre.
Study: NCT06069323

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation
Description: Pediatric patients with ASD and ADHD will be randomized both in active and sham groups.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation
Description: Pediatric patients with ASD and ADHD will be randomized both in active and sham groups.
Study: NCT06290219

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: platelet-rich plasma combined with hyaluronic acid
Description: The project investigator injects plasma mixed with hyaluronic acid into the nasal septum and the medial side of the middle turbinate of the patient's nasal cavity under a nasal endoscope.
Study: NCT05894603

Intervention type: DRUG
Intervention: Nirmatrelvir/ritonavir
Description: Nirmatrelvir/ritonavir

Intervention type: DRUG
Intervention: Molnupiravir
Description: Molnupiravir
Study: NCT05756322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBS-007
Description: Open Label.
Study: NCT05835843

Intervention type: OTHER
Intervention: In-Person and Remote Disease Assessment
Description: Disease severity will be assessed during the in-person visit and standardized digital photographs of different body regions and/or the full body will be collected for remote evaluations by external dermatologists.

Intervention type: OTHER
Intervention: In-Person and Remote Disease Assessment
Description: Disease severity will be assessed during the in-person visit and standardized digital photographs of different body regions and/or the full body will be collected for remote evaluations by external dermatologists.

Intervention type: OTHER
Intervention: In-Person and Remote Disease Assessment
Description: Disease severity will be assessed during the in-person visit and standardized digital photographs of different body regions and/or the full body will be collected for remote evaluations by external dermatologists.
Study: NCT06391268

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Technique (EFT) works on cognitive and energetic levels.
Description: Emotional Freedom Technique (EFT) works on cognitive and energetic levels.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Technique (EFT) works on cognitive and energetic levels.
Description: Emotional Freedom Technique (EFT) works on cognitive and energetic levels.
Study: NCT05575466

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples
Description: Hemostatic biomarkers
Study: NCT06290219

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinc Gluconate 10 MG Oral Tablet
Description: one tablet three times a day for a period of 12 weeks
Study: NCT05575466

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples
Description: Hemostatic biomarkers

Intervention type: DIAGNOSTIC_TEST
Intervention: Questionnaires
Description: Eating Disorder Inventory - third version (EDI-3) Eating Disorder Quality of Life Scale (EDQLS)
Study: NCT06470243

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT06290219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Gluconate 10 MG Oral Tablet
Description: one tablet three times a day for a period of 12 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 4 bottles of phenyl ethyl alcohol, lemon, eucalyptus, and clove oil
Description: Sniffing each odorant for 10 seconds, twice a day for 12 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4 bottles of phenyl ethyl alcohol, lemon, eucalyptus, and clove oil
Description: Sniffing each odorant for 10 seconds, twice a day for 12 weeks
Study: NCT06470243

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabazitaxel
Description: Given IV
Study: NCT04353024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyltryptamine (DMT)
Description: Intravenous DMT bolus and/or DMT maintenance perfusion over 90 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyltryptamine (DMT)
Description: Intravenous DMT bolus and/or DMT maintenance perfusion over 90 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyltryptamine (DMT)
Description: Intravenous DMT bolus and/or DMT maintenance perfusion over 90 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyltryptamine (DMT)
Description: Intravenous DMT bolus and/or DMT maintenance perfusion over 90 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Intravenous saline bolus and/or saline maintenance perfusion over 90 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Intravenous saline bolus and/or saline maintenance perfusion over 90 min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intravenous saline bolus and/or saline maintenance perfusion over 90 min
Study: NCT06470243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chest Radiography
Description: Undergo chest x-ray
Study: NCT05520268

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital music rehabilitation (DMR)
Description: DMR comprises both receptive and expressive musical activities (listening and reminiscing to music, singing, and moving to music) held in small groups (8 PWDs/group) for a duration of 10 weeks (2x60 min sessions/week) and implemented using a novel digital music content service called HILDA. In HILDA, there are a number of stand-alone musical programs hosted by a virtual presenter which the PWDs can follow and through which they can interact. The DMR sessions are moderated by an instructor (care home staff member or research assistant). For PWDs living in a care home, the DMR is implemented as live sessions held at the care home using a HILDA box connected to a TV screen and operated via a remote controller by the instructor. For PWDs living at home, the DMR is implemented as virtual sessions using a video communication platform that allows the instructor to stream and control the HILDA service and the participants to see and hear each other and interact.
Study: NCT05470829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZM-H1505R
Description: Part 1 dosage form:75mg dosage:Tablet frequency: Quaque die duration: Day1; Day 4\~ Day 14~Cohort 1 of Part 2 dosage form:50mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 2 of Part 2 dosage form:100mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 3 of Part 2 dosage form:200mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZM-H1505R
Description: Part 1 dosage form:75mg dosage:Tablet frequency: Quaque die duration: Day1; Day 4\~ Day 14~Cohort 1 of Part 2 dosage form:50mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 2 of Part 2 dosage form:100mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 3 of Part 2 dosage form:200mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZM-H1505R
Description: Part 1 dosage form:75mg dosage:Tablet frequency: Quaque die duration: Day1; Day 4\~ Day 14~Cohort 1 of Part 2 dosage form:50mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 2 of Part 2 dosage form:100mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 3 of Part 2 dosage form:200mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZM-H1505R
Description: Part 1 dosage form:75mg dosage:Tablet frequency: Quaque die duration: Day1; Day 4\~ Day 14~Cohort 1 of Part 2 dosage form:50mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 2 of Part 2 dosage form:100mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 3 of Part 2 dosage form:200mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ZM-H1505R Placebo
Description: Part 1 dosage form:75mg dosage:Tablet frequency: Quaque die duration: Day1; Day 4\~ Day 14~Cohort 1 of Part 2 dosage form:50mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 2 of Part 2 dosage form:100mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 3 of Part 2 dosage form:200mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ZM-H1505R Placebo
Description: Part 1 dosage form:75mg dosage:Tablet frequency: Quaque die duration: Day1; Day 4\~ Day 14~Cohort 1 of Part 2 dosage form:50mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 2 of Part 2 dosage form:100mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 3 of Part 2 dosage form:200mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28
Study: NCT05668260

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodegradable Stent
Description: A trans-anastomotic biodegradable internal stent (ARCHIMEDES™) will be placed between the main pancreatic duct (MPD) and the enterotomy in the jejunum just after the completion of the posterior suture of duct-to-mucosa. The biodegradable stent will then be shaped according to the angle of the jejunal loop in order to minimise the risk of displacement. The adequate length of the stent will be chosen according to the length of the jejunal loop.
Study: NCT06337292

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Incisional Negative Pressure Wound Therapy (NPWT)
Description: Participants in the treatment group will be standardized and will receive incisional NPWT using the any incisional VAC system that can apply 75-125mmHg continuous suction to the incision. The VAC sponge will be placed over the surgical wound at least 2cm in width and \>3cm in length.
Study: NCT04683718

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Permanent implant of a BIOTRONIK Prospera SCS (Spinal Cord Stimulation) System with HomeStream Remote Management
Description: The Prospera SCS System is a rechargeable, 16-electrode, MRI conditional Spinal Cord Stimulation system that delivers electrical stimulation to the dorsal column of the spinal cord for the treatment of chronic intractable pain of the trunk and/or limbs.
Study: NCT04489485

Intervention type: BEHAVIORAL
Intervention: Teen Depression Module used for care
Description: All teens coming for routine well child care to the enhanced group PCPs will have depression screening with strengths and goals and a depression screen with follow up suggestions for activities to help any depression symptoms, and treatment using the Teen Depression Module and offered a depression chabot. Suicide screening will be conducted.

Intervention type: BEHAVIORAL
Intervention: Teen Depression Module used for care
Description: All teens coming for routine well child care to the enhanced group PCPs will have depression screening with strengths and goals and a depression screen with follow up suggestions for activities to help any depression symptoms, and treatment using the Teen Depression Module and offered a depression chabot. Suicide screening will be conducted.
Study: NCT05470829

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ZM-H1505R Placebo
Description: Part 1 dosage form:75mg dosage:Tablet frequency: Quaque die duration: Day1; Day 4\~ Day 14~Cohort 1 of Part 2 dosage form:50mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 2 of Part 2 dosage form:100mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 3 of Part 2 dosage form:200mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ZM-H1505R Placebo
Description: Part 1 dosage form:75mg dosage:Tablet frequency: Quaque die duration: Day1; Day 4\~ Day 14~Cohort 1 of Part 2 dosage form:50mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 2 of Part 2 dosage form:100mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 3 of Part 2 dosage form:200mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28
Study: NCT06470243

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest Radiography
Description: Undergo chest x-ray

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT05383313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Effect of psilocybin on treatment-resistant depression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Hydrochloride
Description: Effect of ketamine on treatment-resistant depression

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam Ph. Eur 9.0
Description: Effect of midazolam on treatment-resistant depression
Study: NCT06470243

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study: NCT04840992

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation
Description: Aerogen Solo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation
Description: Aerogen Solo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation
Description: Aerogen Solo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation
Description: Aerogen Solo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation
Description: Aerogen Solo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation
Description: Aerogen Solo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation
Description: Aerogen Solo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation
Description: Aerogen Solo
Study: NCT05281978

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decrease Sedentary Time + Increase MVPA group
Description: 12 week home-based exercise program to promote engagement of 150 min/week of moderate-vigorous intensity exercise; personalized step count goals to increase daily volume of physical activity and displacement of sedentary time

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Increase MVPA group
Description: 12 week home-based exercise program to promote engagement of 150 min/week of moderate-vigorous intensity exercise
Study: NCT06021353

Intervention type: DEVICE
Group type: OTHER
Intervention: UV fs-Laser
Description: Stationary scanning spot femtosecond laser used for corneal flap creation during refractive surgery
Study: NCT04840992

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation
Description: Aerogen Solo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation
Description: Aerogen Solo